Nov. 12 at 8:57 PM
$SNGX Soligenix (NASDAQ: SNGX) is a small clinical-stage biotech working on HyBryte™, a photodynamic therapy for cutaneous T-cell lymphoma (CTCL).
The company has already started its confirmatory Phase 3 trial — safety milestones have been cleared, and top-line results are expected in the second half of 2026.
Financially, it’s still very high risk: limited cash flow, recent dilution, and dependence on new funding rounds.
It might be interesting for those who understand biotech volatility and can handle long-term uncertainty, but it’s definitely not for conservative or risk-averse investors.
